Table 3.
Effect of mecillinam and mecillinam in combination with other beta-lactams for the treatment of bacteremia caused by Enterobacteriaceae
| Reference | Cases | Clinical success | Bacteriological success (without relapse/reinfections) |
|---|---|---|---|
|
Mecillinam
| |||
| Frimodt-Møller and Ravn32 | 2 | 2/2 | 2/2 |
| Ekwall et al30 | 3 | 2/3 | 2/3 |
| Ode et al39 | 3 | 3/3 | 3/3 |
| Trollfors et al38 | 7 | 3/7 | 6/7 |
| Total | 15 | 10/15 (67%) | 13/15 (87%) |
|
Mecillinam in combination with other beta-lactams | |||
| Frimodt-Møller and Ravn32 | 3 | 3/3 | 3/3 |
| Ekwall et al30,a | 10 | 8/10 | 8/10 |
| Rotstein and Farrar37 | 7 | 7/7 | 7/7 |
| King et al35 | 25 | 24/25 | 24/25 |
| Eriksson et al31 | 4 | 4/4 | 2/2 |
| Jernelius et al34,b | 4 | 4/4 | 2–3/4 |
| Cronberg et al29 | 12 | 7/12 | 7/12 |
| Total | 64 | 57/65 (88%) | 53/63 (84%) |
Notes:
a
Twofold doses in 50% of the patients.
b
Since the 1-week therapy was significantly inferior, it is not included in this table.